Ryan Fugate
Psychiatry · Mercer Island, WANPI 1003042797
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,267 of the $4,428 with a category attached, or 73.8%. 18 manufacturers reported payments, led by Livanova USA, Inc. at 41.7% of the total. Reporting peaked in 2019 at $2,654 and has fallen 96.2% since, to $100 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $34.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$574
- Johnson & Johnson$550
- AbbVie$470
- Otsuka America Pharmaceutical, Inc.$216
- Neurocrine Biosciences, Inc.$155
- plus $616 from 12 others
What the payments were for
- Travel & lodging$1,16026%
- Food & beverage$3,26774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 15 | $1,847 |
| Teva Pharmaceuticals USA, Inc. | 20 | $574 |
| Johnson & Johnson | 18 | $550 |
| AbbVie(2 entities) | 28 | $470 |
| Otsuka America Pharmaceutical, Inc. | 12 | $216 |
| Neurocrine Biosciences, Inc. | 7 | $155 |
| Avanir Pharmaceuticals, Inc. | 6 | $129 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $128 |
| Lundbeck LLC | 4 | $90 |
| Vertical Pharmaceuticals, LLC | 3 | $59 |
| Alkermes, Inc. | 2 | $48 |
| Alfasigma USA, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Neuronetics, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,405
- AUSTEDO$253
- SPRAVATO$106
How this compares
$4,428 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 11 | $1,153 |
| Aripiprazole | 30 | $1,093 |
| Gabapentin | 17 | $968 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $833 |
| Lamotrigine | 62 | $692 |
| Bupropion XlBupropion Hcl | 22 | $464 |
| Duloxetine Hcl | 21 | $454 |
| Lithium Carbonate ErLithium Carbonate | 24 | $435 |
| Alprazolam | 50 | $411 |
| Escitalopram Oxalate | 25 | $373 |
| Quetiapine Fumarate | 17 | $355 |
| Mirtazapine | 23 | $352 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 26 | $306 |
| Trazodone Hcl | 47 | $271 |
| Clonazepam | 22 | $269 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Mercer Island
- David DunnerMercer Island$79K
- Cara ErkutMercer Island$14K
- Christina DemopulosMercer Island$9K
- Jeffrey HansenVancouver$2.8M
- Chester RobachinskiSeattle$1.1M
- Larry BornsteinEverett$663K
- Matthew BogoyasYakima$500K
- Pablo ProanoSeattle$112K
- Jesse McClellandSeattle$39K
- Douglas WornellFox Island$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.